Care One Acid Reducer Plus Antacid and Pexidartinib
Determining the interaction of Care One Acid Reducer Plus Antacid and Pexidartinib and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown. MANAGEMENT: If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.
MANAGEMENT: If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: calcium carbonate / famotidine / magnesium hydroxide
Brand name: Dual Action Complete, Duo Fusion, Pepcid Complete
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Care One Acid Reducer Plus Antacid-Pexidartinib Hydrochloride
- Care One Acid Reducer Plus Antacid-Pfizerpen
- Care One Acid Reducer Plus Antacid-Pharaon Tea
- Care One Acid Reducer Plus Antacid-Pharmorubicin Pfs
- Care One Acid Reducer Plus Antacid-Phazyme
- Care One Acid Reducer Plus Antacid-Phazyme Liquid Gas Relief, Maximum Strength
- Pexidartinib-Care One Sleep Aid
- Pexidartinib-Careone Acid Reducer
- Pexidartinib-Careone Hair Regrowth Treatment for Men
- Pexidartinib-Carfilzomib
- Pexidartinib-Carfilzomib Intravenous
- Pexidartinib-Carimene N/F